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Abstract
Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly. We report two
young patients with cystic fibrosis who presented with acute renal insufficiency after 2–3 weeks of oral ciprofloxacin therapy.
The incidence of this adverse effect in children and young adults who have cystic fibrosis is unknown. Multiple mechanisms for
ciprofloxacin-induced nephrotoxicity have been proposed.
 2003 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Ciprofloxacin is commonly associated with acute
renal insufficiency (ARI), but the majority of cases
reported are in older adult patients w1x. Ciprofloxacin is
a useful antibiotic in the treatment of pulmonary exac-
erbations in patients with cystic fibrosis (CF), and many
children and young adult patients receive this drug w2x.
Although the side effect profile of ciprofloxacin is well
known, there is very little data on the incidence of side
effects in younger patients who have CF w3x. Only two
cases of ARI in patients with CF have previously been
reported w4,5x. Typically, adolescent or young adult
patients without CF who have been reported to have
ARI during ciprofloxacin therapy have been overdosed
or been treated with multiple nephrotoxic medication
w1x. We report two younger patients with CF who
presented with ARI after a short course of ciprofloxacin
therapy.
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2. Case 1
A 23-year-old white female with CF due to DF508
and R117H mutations in the cystic fibrosis transmem-
brane conductance regulator (CFTR) gene was being
treated for a pulmonary mycobacterium avium intracel-
lulare complex (MAI) infection. In addition to MAI,
her sputum cultures grew Pseudomonas aeruginosa and
Stenotrophomonas maltophilia. She received isoniazid,
pyridoxine, ethambutol, clarithromycin and ciprofloxa-
cin for approximately 3 months. The ciprofloxacin and
isoniazid were discontinued because of significant nau-
sea and anorexia. Laboratory testing at that time revealed
a creatinine of 0.8 mgydL and blood urea nitrogen of
10 mgydL. She last received an intravenous aminogly-
coside antibiotic 3 months earlier, at which time her
creatinine was 1.1 mgydL.
Three weeks later she was switched to a new drug
regimen consisting of rifabutin 150 mg bid, ethambutol
250 mg tid and ciprofloxacin 750 mg bid (32 mg kgy1
day ) based on MAI antibiotic susceptibility testing.y1
There was no change in her pulmonary status, but she
developed vomiting while taking this combination of
medications and had significant weight loss. At this
time, she was also taking constant doses of theophylline,
nortriptyline, vitamins and albuterol. Three weeks after
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starting the new triple antibiotic regimen, laboratory
testing demonstrated a creatinine of 5.1 mgydL and
blood urea nitrogen of 44 mgydL. Urinalysis demon-
strated 5–10 white blood cells and occasional red blood
cells; no other abnormalities were present in the urine
sediment. Ciprofloxacin was discontinued and her renal
function improved rapidly without further therapy. She
continued to take rifabutin and ethambutol. Nine days
later her creatinine was 1.3 mgydL and blood urea
nitrogen was 21 mgydL. Her creatinine returned to a
baseline of 0.8 mgydL within 3 weeks.
3. Case 2
A 16-year-old white female with CF who was homo-
zygous for the DF508 mutation in the CFTR gene
developed symptoms of sinusitis, including headaches
and post-nasal drip. She was prescribed oral ciproflox-
acin 750 mg bid (38 mg kg day ). After 10 days ofy1 y1
therapy, she developed severe flank pain. At that time,
laboratory studies revealed a creatinine of 3.2 mgydL
and blood urea nitrogen of 29 mgydL. A renal ultra-
sound demonstrated slightly increased echogenicity of
both kidneys but no other abnormalities were observed.
Urinalysis was unremarkable. The patient’s other medi-
cations included pancreatic enzymes, omeprazole, azith-
romycin, trimethoprim-sulfamethoxazole, dornase-alfa,
inhaled tobramycin and a salmeterol-fluticasone diskus.
She last received an intravenous aminoglycoside antibi-
otic 3 months prior to this episode; at that time her
creatinine was 0.5 mgydL. Ciprofloxacin was discontin-
ued and her creatinine fell to 1.2 mgydL in 3 days and
returned to 0.5 mgydL within 3 weeks.
4. Discussion
The adverse effects of ciprofloxacin have been well
described w3x. It has been shown that the incidence of
adverse effects of ciprofloxacin in pediatric patients
without CF is similar to that reported in adults w6,7x.
Central nervous system effects of ciprofloxacin can be
serious, resulting in seizures, depression, anxiety, eupho-
ria, somnolence and insomnia, but do not occur with
great frequency w3x. Phototoxicity has been described in
both adult and pediatric patients; while nausea, vomiting
and diarrhea account for the majority of gastrointestinal
effects w3x. Joint toxicity was initially a greater concern
in children than adults based on data from immature
animals w3x. However, data have shown that the preva-
lence of joint toxicity in adults and children is similar
w7,8x. The only reported adverse event exclusive to
children is stained teeth in very young patients w9x. The
renal toxicities associated with ciprofloxacin have been
well described and depending upon the insult can have
multiple presentations including occult hematuria,
decreased renal function, increased renal weight, crys-
talluria and acute interstitial nephritis leading to acute
renal failure w1,3x.
Acute renal insufficiency due to ciprofloxacin has
been primarily documented in adults during the past 15
years w1x. The true incidence of ciprofloxacin-induced
ARI is difficult to determine since many patients are
taking other medications that may affect renal function.
There are a few reports of ARI in patients who have
taken only ciprofloxacin, but these patients often have
diseases that affect renal function w10x. Although the
actual incidence of adverse renal effects attributable to
ciprofloxacin is difficult to determine, there are common
risk factors among those patients who develop ARI.
One characteristic is that ARI tends to occur in older
adult patients. Concomitant disease states including car-
diac transplant, oncologic disease, congestive heart fail-
ure and aortic stenosis, jejunoileal bypass, hematuria,
disseminated intravascular coagulation and septic shock,
rheumatoid arthritis, continent urinary diversion and
cranial trauma have been proposed as precipitating
factors for toxicity w1x. Several patients in these case
reports were also taking other medications that may
have renal toxicity.
Differences in drug metabolism in patients with CF
may predispose them to ciprofloxacin-induced ARI.
However, decreased renal clearance of ciprofloxacin
seems unlikely, as many patients with CF have received
multiple courses of this drug and only a very small
proportion have had significant renal toxicity. Higher
doses of ciprofloxacin could possibly result in an
increased incidence of adverse effects, which may be
significant when treating pulmonary exacerbations in
patients with CF w11x.
The mechanism of action for quinolone nephrotoxicity
has never been clearly elucidated. Allergic interstitial
nephritis (AIN) is often cited as a common cause of
ciprofloxacin nephrotoxicity. The mechanism of injury
is attributed to a type III hypersensitivity reaction w4x.
Allergic interstitial nephritis is usually not related to the
dose of offending agent and renal biopsy must be
performed to obtain a definitive diagnosis. Crystalliza-
tion of ciprofloxacin, most commonly associated with
alkaline urine in animal models, has been suggested as
a cause of ARI w12x. This is thought to be dose
dependent and associated with mild renal disease. How-
ever, since urine pH is rarely alkaline in humans,
crystallization is not a likely cause of ciprofloxacin
toxicity in humans. The formation of urinary complexes
containing drug metabolites, protein and magnesium due
to impaired ability to excrete sodium or to dilute or
concentrate urine has also been proposed as a cause of
quinolone-induced renal toxicity in patients with CF
w12x. In a report of recurrent interstitial nephritis due to
beta-lactam antibiotics in a 13-year-old patient with CF,
the authors postulated that the nephritis was immune-
mediated through humoral or cell-mediated mechanisms
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based on a lack of detectable immune complexes or
anti-tubular basement membrane antibodies w13x. Gran-
ulomatous interstitial nephritis (GIN) is another form of
cell-mediated nephritis, which has been described in
patients taking penicillins and sulfa drugs and may be a
mechanism by which quinolones cause ARI w1x.
Both of the patients in this report received ciproflox-
acin 750 mg twice daily for approximately 2–3 weeks
prior to developing ARI. The renal insufficiency
resolved quickly after ciprofloxacin was discontinued,
suggesting its key nephrotoxic role in these two patients,
and no further therapy was required. Two other cases of
ARI in patients with CF have been reported. A 25-year-
old patient with CF and diabetes mellitus experienced
decreased renal function, an increase in serum creatinine
and flank pain after three courses of ciprofloxacin. The
only abnormal finding on biopsy was epithelial vacuoles
in the distal tubules, a finding that is often associated
with gentamicin toxicity w5x. The only other reported
case of ciprofloxacin-associated ARI in a patient with
CF occurred in an 18-year-old woman who was treated
with 750 mg of ciprofloxacin three times daily (30 mg
kg day ), compared to twice daily in our patients.y1 y1
Renal biopsy revealed discrete interstitial infiltration
without interstitial nephritis and flattened tubular epithe-
lium w4x.
Only two other children have been described with
ciprofloxacin-induced ARI and one of them had a
deliberate overdose leading to acute tubular necrosis
w14x. The other patient was an 11-year-old boy who
developed ARI while being treated with ciprofloxacin
for typhoid fever w15x. Renal biopsy in this latter case
revealed interstitial nephritis.
In conclusion, the cases reported here add to the side
effect profile of an important drug commonly used in
the younger CF patient population. These two cases
constitute half of the published cases of quinolone-
associated ARI in young CF patients. The cases
described are unusual due to the young age of the
patients and we propose that CF plays a role in predis-
posing younger patients to ciprofloxacin-induced
nephrotoxicity. The mechanism by which the renal injury
occurs is currently elusive and most likely multifactorial.
These cases illustrate that ARI can be a significant side
effect of ciprofloxacin therapy especially in younger
patients with CF.
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